Review

STAT3 Target Genes Relevant to Human Cancers

Richard L. Carpenter 1 and Hui-Wen Lo 1,2,*

1 Division of Surgical Sciences, Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA; E-Mail: richard.carpenter@duke.edu (R.L.C.)
2 Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA

* Author to whom correspondence should be addressed; E-Mail: huiwen.lo@duke.edu; Tel.: +1-919-668-6792.

Received: 3 January 2014; in revised form: 22 March 2014 / Accepted: 28 March 2014 / Published: 16 April 2014

Abstract: Since its discovery, the STAT3 transcription factor has been extensively studied for its function as a transcriptional regulator and its role as a mediator of development, normal physiology, and pathology of many diseases, including cancers. These efforts have uncovered an array of genes that can be positively and negatively regulated by STAT3, alone and in cooperation with other transcription factors. Through regulating gene expression, STAT3 has been demonstrated to play a pivotal role in many cellular processes including oncogenesis, tumor growth and progression, and stemness. Interestingly, recent studies suggest that STAT3 may behave as a tumor suppressor by activating expression of genes known to inhibit tumorigenesis. Additional evidence suggested that STAT3 may elicit opposing effects depending on cellular context and tumor types. These mixed results signify the need for a deeper understanding of STAT3, including its upstream regulators, parallel transcription co-regulators, and downstream target genes. To help facilitate fulfilling this unmet need, this review will be primarily focused on STAT3 downstream target genes that have been validated to associate with tumorigenesis and/or malignant biology of human cancers.

Keywords: STAT3; cancer; gene transcription
1. Introduction

Signal transducer and activator of transcription-3 (STAT3), also known as acute phase response factor (APRF), is a DNA-binding transcription factor [1,2]. STAT3 belongs to the STAT family of transcription factors consisting of seven proteins, namely, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. Activated STAT3 translocates into the cell nucleus and binds to the interferon-gamma activated sequence (GAS) within target gene promoters to regulate gene transcription [3]. When cells are exposed to cytokines and growth factors, cytoplasmic STAT3 becomes phosphorylated at tyrosine-705 (Y705) [4]. Classically, phosphorylated STAT3 can homodimerize, as well as heterodimerize with STAT1, and then undergo nuclear transport. However, it is now recognized that unphosphorylated STAT3 also undergoes nucleo-cytoplasmic shuttling and up regulates genes, a large portion of which overlap with those up regulated by phosphorylated STAT3 [5,6]. Phosphorylation of the STAT3 Y705 residue can be induced by cytokines (IL-6, IFN-α), growth factors (EGFR, EGFRvIII, HER2 and PDGFR) and non-receptor tyrosine kinases (Src and all the JAK family proteins) [7–9]. Inactive JAK proteins constitutively bind G-protein coupled receptors, IL-Rs, LIF-R, gp130, and undergo autoprophorylation and activation upon receptor activation. JAK2 activation can be mediated by EGFR and EGFRvIII. STAT3 can also be phosphorylated at Ser727 by ERK, CDK1, ATM and ATR [10]. Evidence to date suggests that Ser727 phosphorylation may be essential for the maximal transcriptional activity of Y705-phosphorylated STAT3 although the true impact of S727 phosphorylation remains somewhat controversial. For example, a study [11] showed that STAT3 activation by a phosphomimetic S727 induced prostate cancer formation independent of Y705 phosphorylation. Dephosphorylation of Y705-phosphorylated STAT3 can occur through protein tyrosine phosphatases, SHP-1/2, Meg2 and protein tyrosine phosphatase delta (PTPRD). The STAT3 pathway can be inhibited by suppressor of cytokine signaling 3 (SOCS3) and protein inhibitors of activated STATs (PIAS) [12–14].

STAT3 is frequently constitutively activated in many human cancers [15–19]. In cancerous cells, STAT3 constitutive activation is common, which is likely due to the aberrant activity of STAT3’s upstream signaling pathways, such as, EGFR, HER2, Src and JAK2. Tumorigenic STAT3 activation has been frequently linked to more malignant cancer behaviors, including growth, epithelial-mesenchymal transition, migration, invasion and metastasis. STAT3 activation is also associated with tumor survival and therapeutic resistance. In immune cells, STAT3 activation often leads to immune suppression and evasion. Together, STAT3 activation in both tumors and immune cells contributes to several malignant phenotypes of human cancers and to compromised anti-cancer immunity, together leading to poor clinical outcomes.

Despite the findings of STAT3 hyperactivation in many cancers, the role of STAT3 in oncogenesis is still unclear and is likely dependent on tumor type and cellular context [20]. Given its ability to regulate both oncogenes and tumor suppressor genes, STAT3 has been reported to promote and inhibit oncogenesis. STAT3 has been shown to induce cancers of the breast [21,22], prostate [11] and skin [23,24]. STAT3 has been reported to transform bone marrow cells into T cell leukemia in a mouse model [20]. In contrast to its positive impact on oncogenesis, activated STAT3 has been shown to suppress c-Myc-mediated transformation of mouse embryonic fibroblasts [20]. STAT3 can promote EGFRvIII-induced glial transformation by forming a nuclear complex with EGFRvIII [25]. The oncogenic role of STAT3 in
gliomas is consistent with the observation that STAT3 activation is rarely detected in normal brain tissues [15,17]. In contrast, in PTEN-proficient mouse astrocytes, STAT3 appeared to behave as a tumor suppressor while simultaneous suppression of PTEN and STAT3 led to astrocyte malignant transformation [25].

The broad influence STAT3 has on cellular function can be attributed to the numerous gene targets that have been identified for STAT3 (Table 1). STAT3 can indirectly regulate genes by mediating expression of other transcription factors or physical association with other transcription factors to enhance or suppress their function in gene regulation. This review will discuss direct STAT3 target genes, which are only considered direct if there is evidence of STAT3 binding either by chromatin immunoprecipitation (ChIP) or electrophoretic mobility shift assay (EMSA). Detection of STAT3 binding by ChIP shows STAT3 binding in cells whereas evidence by EMSA is in vitro but results from either method will be considered as evidence for direct binding. We will discuss the regulation of STAT3 target genes that result in the tumor supporting functions of STAT3, including several transcription factors, apoptosis, tumor immune surveillance, metastasis, tumor angiogenesis, and oncogenic cell signaling. In addition, the direct STAT3 target genes where the outcome is the tumor suppressing functions of STAT3 will be detailed. Finally, STAT3 regulation of genes that may play dual roles in tumor growth will be examined.

**Table 1.** Gene regulation by STAT3.

| STAT3-Regulated Genes | Direct Binding | STAT3 Binding Site(s) | Cell/Tissue Type(s) | Species | Reference |
|------------------------|---------------|-----------------------|--------------------|---------|-----------|
| **Tumor Supporting Functions of STAT3** |
| ↑ c-Fos | EMSA/ChIP | −348 to −339 bp | HepG2, A431 Cells | Human | [19,26,27] |
| ↑ HIF-1α | EMSA/ChIP | −363 to −355 bp | A2058, v-Src-3T3 Cells, B16 Tumors | Human, Murine | [28] |
| ↑ c-Myc | EMSA/ChIP | +84 to +115 bp | HepG2, BAF-G277, KT-3, CCE ES Cells | Human, Murine | [29] |
| ↑ Sox2 | ChIP | −5.7 to −3.3 kb, −528 to +238 bp | CCE ES Cells | Murine | [30] |
| ↑ Nanog | ChIP | −871 to −585 bp | Mouse Embryonic Cells | Murine | [31] |
| ↑ Twist | ChIP | −116 to −107 bp, −103 to −96 bp | A431 Cells | Human | [19] |
| ↑ Zeb1 | ChIP | −310 to −130 bp | SW1116, LoVo Cells | Human | [32] |
| ↓ p53 | EMSA/ChIP | −128 bp | NIH-3T3, MEF Cells | Murine | [33] |
| ↑ Oct-1 | ChIP | −3.5 to −2.5 kb | Eca-109 Cells | Human | [34] |
| **Apoptosis and Proliferation** |
| ↑ Bcl-2 | ChIP | −1022 to −1002 bp | Hela Cells | Human | [35] |
| ↑ Mcl-1 | EMSA | −94 to −86 bp | U266, v-Src-3T3 Cells | Human, Murine | [36,37] |
| ↑ Bcl-xL | ND | −600 to 0 bp | U266 Myeloma, NIH-3T3 Cells | Human, Murine | [38] |
| ↑ Survivin | EMSA/ChIP | −1174 to −1166 bp, −1095 to −1087 bp | MDA-MB-453, NIH-3T3 Cells | Human, Murine | [39] |
### Table 1. Cont.

| STAT3-Regulated Genes | Direct Binding | STAT3 Binding Site(s) | Cell/Tissue Type(s) | Species | Reference |
|-----------------------|----------------|-----------------------|---------------------|---------|-----------|
| **Tumor Supporting Functions of STAT3** |
| ↓ Fas | ChIP | −460 to −240 bp | Myeloma Cells | Human | [40] |
| ↑ Hsp70 | EMSA/ChIP | −122 to −90 bp | VSM, HeLa Cells | Human | [41] |
| ↑ Hsp90α | ChIP | −1142 to −1485 bp | Jurkat Cells | Human | [42] |
| ↑ Hsp90β | EMSA | −643 to −623 bp | VSM Cells | Human | [41] |
| ↑ Cyclin-D1 | EMSA/ChIP | −984 bp, −568 bp, −475 bp, −239 bp | 293T, 3Y1, NIH-3T3, 2Rg Cells | Human | [43–45] |
| **Immune Suppression and Inflammation** |
| ↑ IL-10 | EMSA/ChIP | −120 to −111 bp | RPMI-8226 B Cells | Human | [46] |
| ↑ IL-23 | ChIP | −1159 to +160 bp | B16 Tumors | Murine | [47] |
| ↑ TGF-β | ChIP | −3155 to −2515 bp | CD4+ T Cells | Murine | [48] |
| ↑ COX-2 | ChIP | −134 to −127 bp | U87MG Cells | Human | [49] |
| **Metastasis** |
| ↑ MMP-1 | EMSA/ChIP | −79 to −42 bp | T24, HT-29 Cells | Human | [50] |
| ↑ MMP-2 | EMSA | −1657 to −1620 bp | C4 K1735 Cells | Murine | [51] |
| ↑ MMP-3 | ChIP | −410 to −110 bp | HBVE Cells | Human | [52] |
| ↑ MMP-9 | ChIP | −942 to −934 bp | MCF7 Cells | Human | [53] |
| ↑ Fascin | ChIP | −1095 to −1067 bp | 4T1, MDA-MB-231 Cells | Human | [54] |
| ↑ Vimentin | EMSA/ChIP | −757 to −749 bp | MDA-MB-231, C2C12 Cells | Human | [55] |
| ↑ RhoU | EMSA/ChIP | −1067 to −324 bp | MEF Cells | Murine | [56] |
| ↑ ICAM-1 | EMSA/ChIP | −76 to −66 bp, −175 to −97 bp | HepG2, BV2 Cells | Human | [57] |
| ↑ NGAL | ChIP | −170 bp | Primary Macrophages | Human | [58] |
| ↑ POMC | EMSA | −399 to −374 bp | AtT20 Cells | Murine | [59] |
| ↑ SAA1 | EMSA/ChIP | −226 to +24 bp | HepG2 Cells | Human | [60] |
| **Angiogenesis** |
| ↑ VEGF-A | EMSA/ChIP | −848 bp | v-Src-3T3 Cells | Murine | [61] |
| ↑ bFGF | ChIP | −997 to −989 bp | HUVEC | Human | [62] |
| ↑ HGF | EMSA/ChIP | −149 bp, −110 bp | SP1, RINm5F Cells | Murine | [63,64] |
| **Cell Signaling** |
| ↑ AKT | ChIP | Proximal −2.2 kb | 293 Cells | Human | [65] |
| ↑ PIM-1 | ChIP | −934 to −905 bp | Microglial Cells | Murine | [66] |
| ↑ TNF-R2 | ChIP | −1578 bp, −364 bp | SW480 Cells | Human | [67] |
| ↑ S1P-R1 | EMSA/ChIP | −588 bp | MB49 Cells, B16 Tumors | Murine | [68] |
| ↑ MUC-1 | EMSA/ChIP | −503 to −495 bp | T74D, ZR-75-1 Cells | Human | [69,70] |
| Tumor Suppressing Functions of STAT3 |
|-------------------------------------|
| **Transcription Factors**           |
| ↑ FOXO1 ChIP −515 bp CD4+ T Cells Murine [71] |
| ↑ FOXO3A ChIP +196 bp CD4+ T Cells Murine [71] |
| ↑ Foxp3 ND Intron 1 293 Cells Human [72] |
| ↓ Necdin EMSA/ChIP −588 bp v-Src-3T3 Murine [73] |
| **Survival and Metastasis**          |
| ↑ p21\textsuperscript{CIP1/WAF1} EMSA/ChIP −4183 bp −2540 bp −640 bp MG63, A431, HT-29, WiDr, HepG2 Cells Human [74–76] |
| ↑ PI3K p50\textalpha ChIP −276 bp Mammary Gland Murine [77] |
| ↑ PI3K p55\textalpha ChIP −624 bp Mammary Gland Murine [77] |
| **Tumor Immune Surveillance**        |
| ↑ IL-6 ChIP −73 to −54 bp NIH-3T3, CT26 Murine [78–80] |
| ↓ TNF-α ND −1452 bp Macrophages, SCK1 Murine [80,81] |
| ↓ IFN-γ ChIP 105 to 542 bp T Cells Human Murine [78,80,82] |
| ↓ RANTES EMSA/ChIP −120 to −1 bp PC3, NIH-3T3 Cells Human Murine [78,80,83] |
| ↑ CRP EMSA −112 to −105 bp Hep3B Cells Human [84] |
| ↑ STAT1 ChIP −604 to −596 bp MDA-MB-468 Cells Human [85] |
| ↑ RORγt ChIP 1st Intron TH17 Cells Murine [86] |
| ↑ RORα ChIP 1st Intron TH17 Cells Murine [86] |
| ↑ BATF ChIP 2nd Intron TH17 Cells Murine [86] |
| ↑ IRF4 ChIP Proximal Promoter TH17 Cells Murine [86] |
| ↑ IL-6Ra ChIP 1st Intron TH17 Cells Murine [86] |
| ↑ IL-23R ChIP UD TH17 Cells Murine [86] |
| ↑ IL-17A ChIP −144 bp TH17 Cells Murine [86,87] |
| ↑ IL-17F ChIP −309 bp −326 bp TH17 Cells Murine [86,87] |
| **Other**                            |
| ↑ TIMP-1 EMSA/ChIP −49 to −41 bp HepG2, WI38, CD4+ T Cells Human Murine [88,89] |
| ↑ JunB EMSA −196 to −91 bp HepG2 Cells Human [26,90] |
| ↑ iNOS EMSA/ChIP −142 to −130 bp −84 to −60 bp A431 Cells Human [18] |
| ↑ CDC25A ChIP −222 to +58 bp HepG2, Saos Cells Human [91] |

* Direct binding required evidence by ChIP or EMSA; ND = Not determined; UD = Undescribed.
2. Tumor Supporting Functions of STAT3

STAT3 can promote tumor growth by mechanisms within the tumor cell as well as in the tumor microenvironment. As will become clear, STAT3 can directly regulate genes leading to multiple tumor promoting processes from cell survival, invasion, angiogenesis, and immune escape. In addition, STAT3 can regulate other transcription factors that also support tumor growth, thus STAT3 can also indirectly support tumor growth by promoting survival, angiogenesis, metastasis, and even pluripotency.

2.1. Transcription Factors

There is a broad range of transcription factors that are regulated by STAT3 and none likely have as many broad functions as c-Fos and HIF-1α. Cellular Fos (c-Fos) is a member of the activating protein-1 (AP-1) transcription factor complex composed of dimers from the Jun (c-Jun, JunB, and JunD) and Fos (c-Fos, FosB, Fra1, and Fra2) families. AP-1 is frequently up regulated in several cancer types and also has broad influences supporting tumor inflammation, angiogenesis, and suppression of apoptosis among others [92]. STAT3 has been shown to up regulate c-Fos expression in both hepatocellular and epidermoid carcinoma cells and results indicated this was a result of direct interaction of STAT3 with the c-Fos gene promoter [19,26,27]. Hypoxia inducible factor 1 alpha (HIF-1α) combines with HIF-1β, which is constitutively expressed, to form a dimer that can regulate a multitude of genes that result in tumor growth and progression. The HIF-1 complex is up regulated in multiple cancer types and promotes tumor growth by inducing genes that promote angiogenesis, invasion, and alters cell metabolism to be more characteristic of cancer cells [93]. HIF-1α can be regulated transcriptionally but also by post-translational mechanisms. STAT3 has been shown to increase HIF-1α levels by extension of protein half-life but also induction of HIF-1α transcription in human and mouse melanoma cells [28,94]. The HIF1A gene was found to contain STAT3 binding sites and STAT3 was confirmed to directly bind the HIF1A gene promoter [28]. While STAT3 can directly regulate several genes that support tumor growth, these effects are compounded by the upregulation of c-Fos and HIF-1α expression. STAT3, c-Fos, and HIF-1 alone can support a multitude of processes that promote initiation and progression of tumors.

STAT3 has been shown to be dysregulated in cancer stem cells [95]. Thus, it is not surprising that STAT3 targets several transcription factors that can promote or support stemness. The genes for c-Myc, Sox2, and NANOG have been shown to be intimately involved in the pluripotency of cells [96]. Expression of STAT3 has been shown to up regulate all three of these transcription factors [29–31]. ChIP assays have confirmed that STAT3 can directly associate with the promoter of all three of these genes in embryonic stem cells [29–31]. In addition, HIF-1 has also been shown to support cancer stem cell renewal [97]. Thus, STAT3 can directly up regulate multiple transcription factors that can reprogram cells to induce and sustain pluripotency supporting a cancer stem cell phenotype.

A key step in the metastasis of carcinomas is the conversion of epithelial cancer cells to mesenchymal cancer cells called epithelial-to-mesenchymal transition (EMT). A vital point in EMT is the down regulation of E-cadherin expression, which ultimately promotes intercellular dissociation allowing cell migration, resistance to anoikis, and resistance to chemotherapy among others [98]. This advancement of the EMT program is achieved by expression of transcriptional repressors. Our lab has shown that
STAT3 mediates EGF-induced expression of the repressor Twist in epidermoid and mammary carcinoma cells [19]. We found STAT3 binding sites within the Twist1 promoter and showed direct binding of STAT3 via ChIP [19]. In addition to Twist1, STAT3 has also been shown to up regulate expression of ZEB1, another E-cadherin repressor [32]. They observed STAT3 could also directly associate with the ZEB1 promoter in colorectal carcinoma cells [32]. These studies implicate STAT3 as an inducer of EMT and ultimately tumor progression toward metastasis.

STAT3 also has an indirect effect on cell proliferation by regulating Oct-1 and p53. Octamer transcription factor-1 (Oct-1) is a widely-expressed transcription factor that can induce expression of genes promoting anaerobic metabolism but also promotes cell proliferation [99,100]. Knockdown of STAT3 suppressed Oct-1 expression in esophageal squamous cancer cells [34]. STAT3 was also shown to directly bind the gene promoter for Oct-1 to regulate its expression [101]. Upregulation or activation of p53 occurs in response to many cell stressors from genetic abnormalities to oxidative stress and can potently induce apoptosis and cell cycle arrest [102]. Induction of STAT3 by expression of v-Src has been shown to suppress p53 levels and this was reversed with expression of a STAT3 dominant negative [33]. The gene promoter for p53 contained multiple STAT3 predicted binding sites but STAT3 could only directly associate with one of these sites (−128 bp) to suppress p53 gene expression [33]. The expression of Oct-1 coupled with down regulation of p53 levels, mediated by direct STAT3 regulation, results in a higher potential for progression through the cell cycle and uncontrolled proliferation characteristic of cancer cells.

2.2. Apoptosis and Proliferation

Apoptosis is regulated by two primary pathways: the extrinsic and intrinsic pathways. The extrinsic pathway is initiated by ligands binding to death receptors (e.g., Fas ligand and Fas), which directly activate caspases to initiate the apoptosis program. The intrinsic pathway is regulated at the mitochondria whereby the balance of pro-apoptotic (e.g., Bim, Bad, Bik, PUMA, and NOXA) and anti-apoptotic (e.g., Bcl-2, Bcl-xL, Mcl-1, A1, and Bcl-w) proteins from the Bcl-2 protein family determine the integrity of the mitochondrial membrane. Upon accumulation of pro-apoptotic proteins, mitochondrial outer membrane permeabilization (MOMP) occurs resulting in release of cytochrome c from the mitochondria forming the apoptosome to activate caspases and initiate apoptosis. Several of these proteins have been discovered to be STAT3 target genes.

Anti-apoptotic Bcl-2 proteins, such as Bcl-2 and Mcl-1, interact with the pore-forming proteins Bax and Bak preventing their induction of MOMP and ultimately apoptosis. After induction of both Bcl-2 and STAT3 with phospholipase D in HeLa cells, the Bcl-2 gene was found to contain STAT3 binding sites [35]. STAT3 was found to directly associate with the Bcl-2 gene promoter and up regulate Bcl-2 expression thereby suppressing apoptosis in these cells [35]. Binding sites for STAT3 were also found in the gene promoter for Mcl-1 and inhibition of STAT3 resulted in decreased Mcl-1 levels in peripheral leukocytes [8,103,104]. EMSA experiments later showed that STAT3 can directly bind these STAT3 elements within the MCL1 promoter and drive gene activation in LGL leukemia cells [37]. Another anti-apoptotic protein, Bcl-xL, was also seen to be up regulated with STAT3 expression [38]. Serial truncation of the Bcl-xL gene promoter revealed the proximal region of the promoter was required for STAT3-induced activation of the Bcl-xL gene but direct binding was not assessed [38].
Caspases are the terminal effectors of the apoptosis program and can be directly activated as well as directly inhibited. Aside from the indirect regulation of caspases by the Bcl-2 protein family, caspases can be directly activated by death receptors. One such receptor is the Fas receptor, which binds the Fas ligand and uses the intracellular death domain to directly activate caspases to initiate apoptosis. Expression of a dominant-negative STAT3 mutant induced expression of Fas and, in addition, cells lacking c-Jun were responsive to Fas ligand indicating presence of the receptor [40]. The Fas gene promoter was found to contain binding sites for both STAT3 and AP-1 and mutation of both of these sites increased Fas gene activation greater than mutation of either site alone indicating these two sites likely work together to repress Fas expression [40]. Both EMSA and ChIP assays confirmed that STAT3 and c-Jun bind the Fas gene (TNFRSF6) in a complex in order to repress Fas expression [40].

Caspases can also be directly inhibited by inhibitor of caspases (IAPs), such as survivin, which interact with and suppress activation of caspases to block apoptosis. STAT3 expression has been shown to induce expression of survivin and suppress apoptosis [39]. Both EMSA and ChIP assays confirmed that STAT3 could directly associate with the survivin promoter to induce expression [39].

Heat shock proteins (Hsps) are typically expressed in response to acute cell stress to ensure proteins are folded correctly and to maintain integrity of existing proteins. Hsp proteins are commonly overexpressed in multiple malignant cell types and support tumor growth by protecting oncogenic proteins from degradation [105]. It was observed that thrombin could induce expression of Hsp70 and Hsp90β in vascular smooth muscle cells (VSMCs), which was inhibited by suppression of STAT3 signaling [41]. Experiments using EMSA identified that both STAT3 and STAT1 could bind to a sequence in the Hsp70 gene promoter as well as to a sequence in the Hsp90β gene promoter [41]. In addition, the Hsp90α gene promoter was found to contain the GAS binding sequence [42]. Investigators found that in quiescent Jurkat cells, STAT1 was constitutively bound to this GAS sequence in the Hsp90α gene promoter but heat shock induced binding of STAT3 and HSF1, in addition to STAT1, leading to increased Hsp90α mRNA levels [42]. IFN-γ treatment prevented additional binding of STAT3 and HSF1 to the Hsp90α GAS sequence inhibiting induction of Hsp90α expression with heat shock [42].

In addition to suppressing apoptosis, STAT3 also functions to up regulate proliferation by promoting entry to the cell cycle. The cell cycle is regulated by waves of expression of proteins that drive the cell cycle forward during each phase. In particular, the cyclin D proteins regulate the G1/S-phase transition as the cyclin D proteins (D1, D2, and D3) increase expression leading to interaction with and activation of cyclin dependent kinases 4 and 6 (CDK4/6), which phosphorylates the retinoblastoma (Rb) protein to initiate S-phase [106]. Thus, induction of cyclin D proteins, including cyclin D1, promotes entry into the S-phase and cell proliferation. Early studies showed that an active form of STAT3 could induce cyclin D1 whereas a STAT3 dominant negative could suppress Src-induced cyclin D1 expression [45]. A later study identified STAT3 binding sites within the cyclin D1 gene and observed direct association of STAT3 with the promoter and induction of proliferation [44]. Tumor growth is the result of uncontrolled cell proliferation due to flux through the cell cycle combined with suppression of normal cellular death signals. Thus far, STAT3 has been shown to directly affect both of these mechanisms by upregulating anti-apoptosis proteins as well as cyclin D1 giving substantial reason to those targeting STAT3 for suppressing tumor growth.
2.3. Immune Suppression and Inflammation

STAT3 has been elegantly shown to promote tumor evasion of the immune system [80,107]. STAT3 achieves promoting tumor immune evasion by directly upregulating expression of multiple cytokines that suppress immune function. In addition, STAT3 also up regulates the pro-inflammatory intracellular enzyme COX-2. STAT3 has been shown to indirectly affect several genes related to antigen presentation that cause immune suppression [107,108] but this discussion will focus primarily on genes that STAT3 regulates directly.

Interleukin-10 (IL-10) is an immunosuppressive cytokine that suppresses the production of pro-inflammatory cytokines such as TNF-α and IL-1 and reducing cell surface expression of antigen-presenting proteins. IL-10 is induced by STAT3 in human RPMI 8226.1 B cells [46,109,110]. It was later confirmed that STAT3 could directly associate with the IL10 promoter in these cells [46]. IL-23 is another immune suppressing cytokine that has been shown to reduce tumor infiltration by CD8+ T cells and promote tumor angiogenesis [111]. IL-23 levels were seen to be reduced with knockdown of STAT3 and further examination revealed a STAT3 binding site on the IL-23 gene promoter [47]. A ChIP assay confirmed direct association of STAT3 with this promoter [47]. TGF-β is a cytokine that can suppress Th1 and Th2 cells in addition to its promotion of EMT on epithelial tumor cells. Introduction of an active STAT3 increased expression of TGF-β1 [48]. A search of the TGF-β1 gene found STAT3 binding sites within the promoter and ChIP assay confirmed direct association of STAT3 to the TGF-β1 gene promoter [48]. Thus, STAT3 has a very direct role in suppressing tumor immune surveillance and function by regulation of these cytokines.

Cyclooxygenase-2 (COX-2) is an inducible prostaglandin synthase that is involved in several pathological processes related to inflammation and is up regulated in several types of cancers [112]. Our lab observed increased COX-2 levels with the presence of nuclear EGFR in U87MG human glioblastoma cells [49]. COX-2 expression was further enhanced in these cells with co-expression of an active form of STAT3 [49]. We found a STAT3 target sequence in the COX-2 gene promoter and the STAT3-EGFR complex was found to associate directly with this promoter sequence to induce activation of the gene for COX-2 [49]. These results indicate a significant function of STAT3 is to suppress immune function and promote tumor survival. However, these do not entirely encompass the effect of STAT3 on immune function. Other roles are discussed in the section below on the dual roles of STAT3 in tumor growth.

2.4. Metastasis

Tumor metastasis indicates the spread and implantation of tumor cells from the primary tumor site to distant tissues. Tumor metastasis is generally associated with disease progression, decreased survival, and decreased response to therapy. There are many steps and requirements for tumor cell metastasis including detachment of tumor cells from primary tumors, invasion of these cells out of the primary tumor, entry to a transportation system (i.e., lymphatic system), and implantation into the new tissue site. STAT3 has been shown to up regulate several genes that support multiple functions required for metastasis.
A key step in metastasis is invasion of cells out of the primary tumor site into neighboring tissues. In order for invasion to occur, there is often release of proteases from the tumor cell that degrade extracellular matrix allowing passage of the migrating cell. Proteases also play a role in angiogenesis as pro-angiogenic growth factors are often released from matrix degraded by proteases and they also degrade basement membrane for endothelial cell migration. The matrix metalloproteinase (MMP) family of proteases are zinc-dependent and are capable of degrading many types of extracellular matrix proteins and several family members are confirmed STAT3 target genes. MMP-1 was observed to be up regulated in a STAT3-dependent manner in human colorectal adenocarcinoma and urinary bladder transitional cell carcinoma cells [50,113]. The \textit{MMP1} gene was found to contain a STAT3 and an AP-1 binding site and mutation of either the STAT3 or AP-1 site ablated STAT3-mediated gene activation [50,113]. Further investigation revealed both STAT3 and c-Jun were directly bound to the \textit{MMP1} promoter in a manner dependent on c-Jun binding [50]. In addition to MMP-1, expression of an active STAT3 was also found to induce transcriptional activation of the gene promoter for MMP-2 in mouse melanoma cells [51]. The MMP-2 gene promoter contained several potential STAT3 binding sites and EMSA showed that STAT3 could directly bind the promoter [51]. STAT3 has been observed to induce activation of MMP-3 in human brain vascular endothelial cells [52]. Analysis of the \textit{MMP3} gene revealed several STAT3 binding sites and a subsequent ChIP assay confirmed direct binding to the gene promoter by STAT3 [52]. Lastly, STAT3 can regulate the gene for MMP-9. In MCF7 human breast cancer cells, stable expression of an active STAT3 increased MMP-9 mRNA levels as well as transcriptional activation of the MMP-9 gene [114]. This study found STAT3 binding to the \textit{MMP9} gene via EMSA and a later study confirmed this result using a ChIP assay [53,114].

Once extracellular matrix is cleared to allow cell migration, the cell requires upregulation of proteins to control the cytoskeleton to allow for cell migration. Fascin is one such protein as it is an actin-bundling protein that promotes tumor cell migration, invasion, and metastasis [115]. The human and mouse fascin gene promoter was found to contain a motif similar to the canonical STAT3 binding site [54]. Activation of STAT3 in murine 4T1 cells or human MDA-MB-231 cells induced expression of fascin [54]. Further analysis with a ChIP assay confirmed that STAT3 could directly associate with the gene promoter for fascin in both breast cancer cell types [54]. Vimentin is a type III intermediate filament and supports the structural integrity of the cell while providing flexibility to the cell to allow cell movement. Vimentin is often used as a marker for the mesenchymal phenotype and expression in epithelial tumor cells often indicates EMT and capabilities for cell migration. The vimentin gene promoter was found to contain a STAT3 binding site within the antisilencer element (ASE) and deletion of this region significantly reduced STAT3-induced transcriptional activation of the vimentin gene in MDA-MB-231 and mouse C2C12 cells [55]. Further analysis showed that STAT3 could directly bind these target sequences from the \textit{VIM} promoter [55]. Lastly, STAT3 has been shown to regulate the GTPase RhoU, which acts on the actin cytoskeleton to stimulate filopodia formation and loss of RhoU inhibits cell migration [116,117]. Gene expression profiling of STAT3-null cells led to the identification of RhoU as a possible STAT3 target gene [56]. Treatment of mouse embryonic fibroblasts (MEFs) with gp130 cytokines induced RhoU mRNA levels whereas STAT3-null cells showed significantly lower RhoU expression [56]. EMSA experiments suggested STAT3 could bind multiple sequences in the RhoU gene promoter and two of these sites (−1,067 bp and −324 bp) were also confirmed binding sites by ChIP analysis [56].
Another protein that supports metastasis is intercellular adhesion molecular-1 (ICAM-1), a membrane adhesion molecule up regulated in inflammatory conditions [118]. ICAM-1 has been shown to have higher levels in tumor tissues and antibody targeting of ICAM-1 induces potent macrophage-dependent antitymoma activity [118,119]. ICAM-1 supports metastasis by making it easier for ICAM-1-expressing tumor cells to separate from each other and invade surrounding tissue [120]. The ICAM-1 gene was identified as having an IL-6 response element [57]. It was seen that STAT3 forms a complex with c-Fos and c-Jun to bind and up regulate the ICAMI gene in HepG2 human hepatocellular carcinoma cells [57].

STAT3 can also regulate genes for secreted proteins that play a role in metastasis. Neutrophil gelatinase associated lipocalin (NGAL), or lipocalin 2, is a secreted glycoprotein that has an immune function to protect against bacterial infection [121]. In addition, it also has several tumor promoting functions including stabilization of MMP-9 and, therefore, promotion of cell invasion [121]. IL-10 has been shown to induce NGAL expression and gene activation in human primary macrophages, which was suppressed with inhibition of JAK/STAT signaling [58]. Analysis of the NGAL gene promoter showed a STAT3 binding site and mutation of this site (-170 bp) reduced NGAL gene activation by IL-10 [58]. A ChIP assay then confirmed STAT3 could directly associate with the NGAL gene promoter [58]. Another secreted protein, proopiomelanocortin (POMC), is a precursor peptide that gives rise to multiple derivative peptides such as α-MSH, a known promoter of the growth and metastasis of melanoma [122]. Leukocyte inhibitory factor (LIF) was observed to induce activation of the gene for POMC and murine pituitary tumor cells [59]. Knowing that LIF activates STAT3 signaling, further search of the gene for POMC showed a STAT3 binding site [59]. Deletion of this region reduced gene activation by LIF and EMSA experiments showed that STAT3 could directly bind this sequence [59].

Lastly, STAT3 has also been found to regulate the gene for serum amyloid A (SAA), which can interact with and alter the composition of the extracellular matrix to promote tumor initiation and progression [123]. The SAA proteins are also a family of acute-phase proteins that are at high levels in serum of cancer patients and may be a cancer biomarker [123]. Expression of STAT3 induced transcriptional activation of the SAA1 and SAA2 genes in HepG2 hepatocellular carcinoma cells whereas a STAT3 dominant negative suppressed their activation [60]. EMSA showed that STAT3 could bind sequences within the SAA1 promoter and did so in a complex with the p65 subunit of NF-κB and the acetyltransferase p300 [60]. Subsequent analysis by ChIP assay confirmed that STAT3 was bound to the SAA1 promoter in a complex with p300 [60].

Taken together, it appears that STAT3 up regulates many genes that support tumor metastasis through a variety of mechanisms. This facet of STAT3 biology likely contributes to the association of STAT3 with metastasis and a poor prognosis in multiple cancer types [16,124–126].

2.5. Angiogenesis

Tumors have high proliferation rates and metabolism. These large amounts of activity require a high demand for oxygen and nutrients. Once tumors reach approximately 2 mm in diameter, the center of the tumor becomes hypoxic, which leads to activation of tumor angiogenesis. Tumor angiogenesis is thought to be regulated by the balance of pro-angiogenic (e.g., VEGF-A and basic fibroblast growth factor)
and anti-angiogenic (e.g., angiostatin and endostatin) factors present in the tumor microenvironment [127]. STAT3 has been shown to up regulate tumor angiogenesis by directly targeting multiple pro-angiogenic factors.

Vascular endothelial growth factor A (VEGF-A) is the most studied and most potent pro-angiogenic growth factor known. STAT3 expression induces VEGF-A protein levels in NIH-3T3 cells and promotes angiogenesis [61]. The gene for VEGF-A was found to have STAT3 binding sites and this study provided evidence that STAT3 can directly bind one of these sites to promote VEGF-A expression [61]. Basic fibroblast growth factor (bFGF) is another well-studied pro-angiogenic growth factor that activates fibroblast growth factor receptors (FGFRs) to promote endothelial cell proliferation and angiogenesis. STAT3 can up regulate bFGF expression in HUVEC cells in response to VEGF stimulation and evidence shows STAT3 can associate directly with the bFGF gene promoter [62]. STAT3 has also been shown to be activated by bFGF suggesting initiation of an autocrine signaling loop that promotes STAT3 activation, bFGF expression, and angiogenesis [128]. Hepatocyte growth factor (HGF) was discovered as a neuronal survival factor but also induces proliferation, migration, and tumor angiogenesis. Introduction of an active Src was seen to induce HGF expression with concomitant STAT3 activation in murine mammary adenocarcinoma cells [63]. The gene for HGF was found to contain STAT3 binding sites and direct association of these sites by STAT3 was observed by EMSA [63]. A later study confirmed binding of STAT3 to the HGF gene promoter via ChIP in response to IL-6 in a rat pancreatic β-cell line [64]. Induction of tumor angiogenesis supports tumor metastasis by delivering nutrients to allow for cell survival but also the new vasculature provides an opportunity for migratory cells to enter the circulation and travel to other tissues for implantation. STAT3 induction of angiogenesis and proteases that support angiogenesis and cell invasion together make a lethal combination in tumor biology.

2.6. Cell Signaling

While JAK-STAT3 signaling could be described as proliferation or survival promoting signaling due to some of the already discussed STAT3 target genes, STAT3 can also directly up regulate genes to promote activation of other signaling pathways to induce proliferation and survival. AKT is a serine/threonine kinase commonly activated by the PI3K signaling pathway and participates in many functions of the cell including proliferation, cell growth, and glucose metabolism among many others [129]. AKT protein levels were seen to be increased with treatment of IL-6 and introduction of an active STAT3 induced transcriptional activation of the AKT1 gene in 293 cells [65]. Several predicted STAT3 binding sites were found in the proximal portion of the AKT1 promoter and multiple ChIP assays confirmed STAT3 was bound to the AKT1 promoter [65]. STAT3 has also been shown to directly regulate the serine/threonine kinase PIM-1, which is a proto-oncogene that regulates several cellular functions including proliferation [130]. One study found that expression of a dominant negative STAT3 resulted in Pim-1 downregulation in murine hematopoietic cells and human CD4+ T lymphoma cells [131]. Another study confirmed that Pim-1 is a direct STAT3 target as STAT3 was able to bind the GAS sequence in the Pim-1 gene promoter in T lymphocytes [7]. A more recent study confirmed these results with ChIP assays in rat microglia cells [66].
Both AKT and PIM-1 are intracellular kinases but STAT3 can also regulate membrane receptors that initiate cell signaling pathways. Tumor necrosis factor alpha (TNF-α) acts on TNF-R1 and TNF-R2 to exert actions on cells. TNF-R1 mediates the pro-apoptotic effects of TNF-α by activation of the intracellular death domain inherent in TNF-R1 whereas TNF-R2 lacks this death domain and promotes cell proliferation in cancer cells [132]. IL-6 was seen to induce expression of TNF-R2 in human colorectal adenocarcinoma cells and further analysis revealed two STAT3 binding sites in the gene promoter [67]. Further assays showed STAT3 could directly associate with the TNF-R2 gene promoter to regulate its activation [67]. Sphingosine-1-phosphate (S1P) interacts with the S1P receptor 1 (S1P-R1), a G-protein coupled receptor, to regulate many cellular functions relevant to cancer including proliferation, migration, invasion, and angiogenesis among others [133]. The S1P-R1 protein was observed to be increased in murine B cell tumors with active STAT3 whereas S1P-R1 was down regulated in tumors lacking STAT3 [68]. STAT3 expression was shown to drive transcriptional activation of the S1P-R1 gene and mutation of predicted STAT3 binding sites in the promoter ablated this activation [68]. STAT3 was ultimately shown to directly bind and regulate the gene promoter for S1P-R1 [68]. Interestingly, this study also observed that activation of S1P-R1 was shown to activate STAT3 forming an autoregulatory loop to further induce expression of the receptor and downstream signaling.

Lastly, STAT3 has been shown to regulate the gene for mucin-1 (MUC-1). MUC-1 is a member of the mucin family of glycoproteins and is a transmembrane protein with the extracellular portion of the protein affording a layer of protection of epithelial linings [134]. MUC-1 is frequently overexpressed in breast cancer and interacts with receptor tyrosine kinases, such as EGFR, to promote their activation and upregulation of proliferative signaling [134]. Upon search of the MUC1 gene to identify regulatory proteins, a STAT3 binding site was identified [70]. IL-6 induced transcriptional activation of the MUC1 gene in human mammary ductal carcinoma cells but this induction did not occur when the STAT3 site was mutated [70]. This study also found that STAT3 could directly associate with a STAT3 binding site within the MUC1 promoter in response to IL-6 but that STAT1 bound to the MUC-1 promoter in response to IFN-γ [70]. These data suggest an even further variety of ways in which STAT3 can support tumor growth. STAT3 appears to support tumor growth on multiple fronts of cell biology and in multiple stages of tumor development and progression. However, despite the overwhelming amount of information that supports STAT3 as an oncogene, there is some evidence that STAT3 can also suppress tumor growth.

3. Tumor Suppressing Functions of STAT3

As described above, STAT3 can directly regulate a host of genes that ultimately support tumor growth and progression such as genes involved in cell signaling, tumor angiogenesis, and metastasis. However, as this article series is making clear, STAT3 also has several tumor suppressive functions as a transcription factor including regulating genes for other tumor suppressing transcription factors and genes that suppress cell proliferation and survival as well as tumor metastasis.
3.1. Transcription Factors

The FOX family of transcription factors is characterized as containing the forkhead box domain allowing DNA binding and this large family has ability for gene induction and repression. The FOXO class of FOX transcription factors are a family of tumor suppressors as they block entry to the cell cycle and are inactivated by phosphorylation by several kinases including AKT and CDK1 [135]. STAT3 has been shown to up regulate both FOXO1 and FOXO3A in CD4^+ T cells [71]. The genes for FOXO1 and FOXO3A were found to have STAT3 binding sites and ChIP assays confirmed direct association of STAT3 with both gene promoters [71]. Within another FOX class, the FOXP3 transcription factor was originally discovered as the master regulator in regulatory T cells [136]. However, further evidence indicates FOXP3 is also a tumor suppressor that is down regulated in several types of carcinomas and has the ability to repress several oncogenes including HER2 and c-MYC and up regulate the tumor suppressor p21^{WAF1/CIP1} [136]. FOXP3 expression was found to be increased by IL-2-induced activation of STAT3 in 293 cells [72]. While they did not confirm STAT3 directly bound the FOXP3 gene, mutation of predicted STAT3 binding sites within the first intron of the FOXP3 gene significantly reduced STAT3-induced transcriptional activation of FOXP3 [72].

Necdin, a member of the melanoma antigen gene (MAGE) family, is a transcriptional repressor that facilitates entry into the cell cycle [137]. Aside from its transcriptional role, Necdin also has the ability to physically associate with p53 to suppress p53-dependent apoptosis promoting survival of post-mitotic neurons [138]. Necdin was identified as a potential STAT3 target via microarray experiments and further investigation revealed that STAT3 could directly bind the gene promoter for Necdin leading to downregulation of Necdin levels in v-Src-expressing NIH-3T3 cells [73]. Together, these studies point to the potentially opposing role STAT3 can have on tumor growth by regulating these tumor suppressing transcription factors.

3.2. Survival and Metastasis

Uncontrolled proliferation and cell survival are key factors in tumorigenesis of primary tumors and metastasis of cells from this primary tumor worsens patient prognosis and treatment options. STAT3 can regulate several tumor suppressing genes in these areas.

The cyclin-dependent kinases (CDKs) have endogenous inhibitors and CDK4/6 is specifically inhibited by the protein p21^{WAF1/CIP1}. STAT3 has been shown to directly bind the gene promoter for p21^{WAF1/CIP1} inducing its expression in multiple cell types including epidermoid carcinoma, colorectal carcinoma, and bone osteosarcoma cells [74–76]. One of these studies identified NcoA/SRC1α as co-factors that bind to the p21^{WAF1/CIP1} gene promoter with STAT3 [76].

The regulation of p21^{WAF1/CIP1} is a more direct effect of STAT3 on regulating the cell cycle and proliferation. STAT3 can also regulate expression of subunits of the PI3K complex to suppress cell survival. The class IA PI3K complex is made up of a catalytic subunit (p110α, p110β, or p110δ) and a regulatory subunit (p85α, p85β, p55α, p55γ, or p50α) that combines to respond to receptor tyrosine kinases. These PI3Ks phosphorylate phosphoinositols allowing recruitment of other kinases, such as AKT, leading to their activation and downstream signaling that typically results in cell survival among other tumor supporting functions. During mammary gland involution, STAT3 has previously been
shown to promote apoptosis leading to post-lactation gland regression [139]. One study found that STAT3 was activated whereas AKT was inactivated in mouse mammary glands undergoing involution [77]. Targeted deletion of STAT3 in these mammary glands resulted in decreased expression of the p55α and p50α PI3K subunits [77]. Similarly, STAT3 activation induced expression of p55α and p50α and this correlated with increased apoptosis during involution [77]. STAT3 binding sites were found in the gene promoters for both p55α and p50α and a ChIP assay confirmed association of STAT3 with these sites [77]. Ultimately, STAT3 was found to promote apoptosis in these cells due to upregulation of p55α and p50α, which inhibited PI3K signaling and AKT activation reducing cell signaling for survival [77]. However, this relationship did not extend to embryonic stem cells suggesting this mechanism may be specific to the mammary tissue or during the involution stage and gland regression [77].

STAT3 can, therefore, have effects that both promote and suppress tumor growth. STAT3 seemingly has many more functions that support tumor growth than to suppress tumor growth. However, there are also a great number of genes that STAT3 regulates that have dual roles in tumor growth.

4. Dual Functions by STAT3 in Tumor Growth

To this point, STAT3 has been discussed purely as supporting tumor growth or purely as suppressing tumor growth. However, STAT3 has also been shown to (1) upregulate and downregulate specific genes involved in tumor growth or (2) regulate genes that may themselves support or suppress tumor growth depending on the context.

4.1. Tumor Immune Function

STAT3 can directly regulate the genes for multiple cytokines, which can lead to enhanced or suppressed tumor immune function. In studies identifying STAT3 as a tumor immune suppressor, one of the observations was decreased levels of IL-6 with increased STAT3 expression in NIH-3T3 cells and murine macrophages [78,80]. However, it was later observed that STAT3 can bind to the gene promoter and up regulate IL-6 in response to IL-32α in a manner dependent on PKCε [79]. These different results may be a result of cellular context as PKCε was a co-factor required for STAT3 binding and upregulation of the IL-6 gene. Similarly, expression of a STAT3 dominant negative has been shown to increase TNF-α levels in murine macrophages [80] whereas another study observed that mutation of the STAT3 binding sites in the gene promoter for TNF-α reduced activation of the TNF-α gene [81]. Although an AP-1 binding site was also found in the gene promoter for TNF-α, AP-1 did not appear to play a role in STAT3-mediated gene activation from the data presented [81].

Similar to these genes, STAT3 also has dual regulation of IFN-γ and RANTES. IFN-γ is a cytokine that promotes immune function by activating NK cells and promoting Th1 cell differentiation among other functions. Studies that found STAT3 suppressed tumor immune surveillance found that STAT3 presence resulted in decreased levels of IFN-γ in murine macrophages [78,80]. However, another study found that IL-12 could activate mTOR and STAT3 phosphorylation and ultimately promote IFN-γ production dependent on mTOR activity [82]. This study also identified STAT3 binding sites within the gene for IFN-γ and confirmed direct binding of STAT3, along with STAT4 and c-Jun, to the gene promoter for IFN-γ in response to IL-12 in human T cells [82]. RANTES is another chemokine that
supports immune function by attraction of T cells and monocytes and inducing T cell proliferation. Similar to IFN-γ, RANTES was observed to be negatively regulated by STAT3 expression in murine macrophages [78,80]. However a later study showed that an unphosphorylated form of STAT3, lacking ability for phosphorylation on Y705, could induce RANTES expression by directly interacting with the gene promoter for RANTES in a complex with the p65 subunit of NF-κB [83]. Together these data show that STAT3 can both up regulate and down regulate the genes for cytokines that support immune function to suppress tumor growth. The differential regulation of these genes by STAT3 appears to be related to what STAT3 co-factors are present and even what form of STAT3 is predominantly present (i.e., phosphorylated vs. unphosphorylated).

STAT3 also regulates several other genes that have immune functions that are not as consistent. C-reactive protein (CRP) is an acute-phase protein that has a rapidly increased expression following acute inflammation and CRP activates the complement system. Circulating CRP levels are associated with an increased cancer risk although it has been concluded this link is not causal [140]. However there are more questions regarding the role the complement system plays in cancer as it has long been thought to promote immune surveillance of developing tumors but it has also been shown to promote tumor growth [141]. Treatment of human hepatocellular carcinoma cells was shown to induce CRP expression, which was dependent on STAT3 binding sites within the CRP promoter [84]. Furthermore, direct association of STAT3 with the CRP promoter was also shown under these conditions [84].

STAT1 is another protein shown to be regulated by STAT3 but may support or suppress tumor growth. STAT1, another member of the STAT family, is activated by IFN-γ and has multiple tumor suppressor functions such as enhancement of immune surveillance and promotion of apoptosis [142]. However, STAT1 has also been shown to support inflammation-associated gastric tumorigenesis [143]. Our lab observed increased STAT1 expression in human mammary adenocarcinoma in the presence of nuclear EGFR, which synergized with co-expression of STAT3 to further enhance STAT1 levels [85]. The STAT1 promoter was found to have several STAT3 binding sites and mutation of these sites suppressed STAT1 gene activation by STAT3 and EGFR co-expression [85]. We further showed that regulation by STAT3 and EGFR was the result of a direct association of STAT3 and EGFR with the STAT1 promoter in a STAT3-dependent manner [85]. Whether STAT3-mediated upregulation of STAT1 and CRP actually supports or suppresses tumor growth is not clear to this point despite both STAT1 and CRP potentially having both pro- and anti-tumor activity.

Lastly, STAT3 has a significant impact on tumor immune function through its role in the development of Th17 T helper cells. Th17 cells were identified by their large production of IL-17, which is unique from Th1 and Th2 cells [144,145]. The function of Th17 cells in tumor immunity is not completely understood as some results suggest pro-tumor activity while others suggest anti-tumor activity [146,147]. Six transcription factors have been identified as critical for Th17 differentiation: STAT3, RORγt, RORα, IRF4, BATF, and HIF-1α [147]. Deletion of STAT3 in mouse CD4⁺ naïve T cells prevents their differentiation into Th17 cells whereas expression of an active STAT3 promotes Th17 differentiation [83,86]. Using ChIP coupled with massive parallel sequencing (ChIP-Seq), STAT3 was identified to bind to the gene promoters for RORγt, RORα, BATF, and IRF4 [86]. RORγt is considered the master regulator of Th17 cell differentiation and STAT3 was found to bind within the first intron of the mouse gene leading to increased expression and promotion of Th17 differentiation [86]. It was mentioned above that STAT3 could also directly up regulate HIF-1α gene expression and
protein half-life [28] possibly indicating, although STAT3 regulation of HIF-1α was observed in melanoma cells, that STAT3 can directly regulate all six transcription factors involved in Th17 cell differentiation. This study also identified STAT3 binding to the genes for IL-23R and IL-6Ra, which supports Th17 development as both IL-6 and IL-23 promote Th17 differentiation [83,86]. In addition, STAT3 was also found to bind the genes for IL-17A and IL-17F suggesting STAT3 also participates in the production of IL-17 that led to the identification of Th17 cells [86]. Although STAT3 promotes Th17 development, Th17 cells themselves may support or suppress tumors. Therefore the regulation of Th17 development by STAT3 is an example of a family of genes regulated by STAT3 that drive cell development and affect tumor immune function.

4.2. Other

STAT3 has also been shown to have differing effects on tumor growth through regulation of TIMPs. The MMP family has natural inhibitors termed the tissue inhibitor of metalloproteinases (TIMPs) that suppress the protease function of MMPs. STAT3 has been shown to directly target the TIMP-1 gene as IL-6 has been observed to up regulate TIMP-1 levels in a STAT3-dependent manner in human hepatocellular carcinoma cells as well as human fibroblasts [89]. A STAT3 binding site was found in the gene for TIMP-1 and deletion of the STAT3 binding sites completely ablates TIMP-1 activation by IL-6 [89]. This site was also confirmed to bind STAT3 using EMSA but further analysis of gene activation showed that binding of AP-1 was required for full activation by STAT3 [89]. A later study confirmed the TIMP-1 gene as a STAT3 target using ChIP-Seq in CD4+ T cells [88]. Considering MMPs promote cancer cell invasion, metastasis, and angiogenesis, it would seem that STAT3 upregulation of an endogenous inhibitor to MMPs is another example of STAT3 showing both oncogenic and tumor suppressor functions. However, TIMP-1 has been shown to have functions outside of MMP inhibition related to growth stimulation, apoptosis suppression, and induction of angiogenesis [148]. Furthermore, TIMP-1 is frequently overexpressed in breast cancer and this is associated with a poor prognosis [148]. STAT3 upregulation of TIMP-1 provides a clear illustration of a gene up regulated by STAT3 but may support or suppress tumor growth depending on the context in which it is expressed.

Another example of a gene that is primarily up regulated by STAT3 but may support or suppress tumor growth is JunB. As mentioned above, JunB is in the family of Jun proteins that make up the AP-1 transcription factor. STAT3 was found to bind to predicted STAT binding sequences within the JUNB promoter in response to IL-6 treatment in HepG2 hepatocellular carcinoma cells [26,90]. While there is a great deal of evidence suggesting AP-1 supports tumor growth, there are also indications that JunB can act as a tumor suppressor in certain contexts [92]. The role of STAT3 in tumor suppression by regulation of JunB has not been made clear but this is an example of a STAT3-regulated gene that may support or suppress tumor growth.

Nitric oxide (NO) is produced in cells by nitric oxide synthases (NOS), in which there are three isoforms: endothelial (eNOS), neuronal (nNOS), and inducible (iNOS) [149]. The expression of eNOS and nNOS are relatively limited to a small number of tissues and are calcium-dependent whereas iNOS is calcium-independent and can be expressed in a large variety of tissues [149]. The expression of iNOS is associated with several types of cancer and the produced NO has many pro-tumorigenic
functions such as activation of signaling pathways and inhibition of DNA repair [149]. However, there are instances in which NO suppresses tumor growth such as enhanced activity of Fas and inhibition of NF-κB [149]. The iNOS gene was identified as a potential target gene for the nuclear EGFR-STAT3 complex [18]. Further analysis of the gene for iNOS found multiple STAT3 binding sites and mutation of these sites reduced transcriptional activation by the STAT3-EGFR complex [18]. Both EMSA and ChIP assays confirmed that STAT3 and EGFR bind to and regulate the gene promoter for iNOS in epidermoid carcinoma cells [18]. This study suggested STAT3 regulation of iNOS supported growth of malignant tumor cells. However, iNOS and NO also have potential tumor suppressing functions and the role of STAT3 in these have not been clearly addressed.

STAT3 can also regulate the dual specificity phosphatase CDC25A, which can remove phosphate from serine, threonine, or tyrosine residues. CDC25A is required for cell cycle progression from the G1 to the S phase [150]. IL-6 induced expression of CDC25A in a STAT3-dependent manner in human hepatocellular carcinoma cells [91]. A ChIP assay found that STAT3 was directly bound to CDC25A promoter in a manner dependent on c-Myc binding [91]. In addition to this mechanism of STAT3-mediated upregulation of CDC25A, this study also observed a mechanism whereby STAT3 suppresses CDC25A. Hydrogen peroxide was seen to induce interaction between STAT3 and retinoblastoma (Rb) protein and this complex occupied the CDC25A promoter in the same proximal region as the STAT3-c-Myc complex to repress expression [91]. This is further evidence suggesting the cellular context may play a significant role in whether STAT3 up regulates or down regulates genes in which STAT3 has dual regulation and, consequently, whether STAT3 supports or suppresses tumor growth.

5. Conclusions

Extensive efforts have been and are being actively invested in developing and testing STAT3-targeted therapy against a variety of human cancers. To date, the clinical testing of the STAT3-targeted therapy is still in the early stage with promising results being reported. To maximize these clinical efforts, a deeper understanding of the STAT3 pathway is urgently needed. To meet this need, additional investigations are required to decipher the full spectrum of STAT3 target genes in the context of different cellular environment and various types of human cancers, gain mechanistic insights into how STAT3 is regulated, deepen our understanding of the existing and novel signaling pathways that crosstalk with STAT3, and to identify novel cellular processes that can be regulated by STAT3 but may have been overlooked.

Acknowledgements

This was supported by the NIH grants K01-CA118423 (Lo) and R01 NS087169-01 (Lo), and the DoD grant W81XWH-11-1-0600 (Lo), and the Intramural Division of Surgical Sciences grants, Dani P. Bolognesi PhD Award and Clarence Gardner PhD Award (Lo).
Author Contributions

Richard L. Carpenter wrote sections 2-4 while Hui-Wen Lo wrote sections 1 and 5. Richard L. Carpenter and Hui-Wen Lo both organized the structure of the manuscript.

Conflicts of Interest

The authors declared no conflict of interest.

References

1. Akira, S.; Nishio, Y.; Inoue, M.; Wang, X.J.; Wei, S.; Matsusaka, T.; Yoshida, K.; Sudo, T.; Naruto, M.; Kishimoto, T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. *Cell* 1994, 77, 63–71.

2. Wegenka, U.M.; Buschmann, J.; Lutticken, C.; Heinrich, P.C.; Horn, F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. *Mol. Cell. Biol.* 1993, 13, 276–288.

3. Darnell, J.E., Jr.; Kerr, I.M.; Stark, G.R. JAK-STAT pathways and transcriptional activation in response to ifns and other extracellular signaling proteins. *Science* 1994, 264, 1415–1421.

4. Fu, X.Y. From PTK-STAT signaling to caspase expression and apoptosis induction. *Cell Death Differ.* 1999, 6, 1201–1208.

5. Liu, L.; McBride, K.M.; Reich, N.C. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. *Proc. Natl. Acad. Sci. USA* 2005, 102, 8150–8155.

6. Yang, J.; Chatterjee-Kishore, M.; Staugaitis, S.M.; Nguyen, H.; Schlessinger, K.; Levy, D.E.; Stark, G.R. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. *Cancer Res.* 2005, 65, 939–947.

7. Matikainen, S.; Sareneva, T.; Ronni, T.; Lehtonen, A.; Koskinen, P.J.; Julkunen, I. Interferon-alpha activates multiple stat proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. *Blood* 1999, 93, 1980–1991.

8. Puthier, D.; Bataille, R.; Amiot, M. IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than Ras/MAP kinase pathway. *Eur. J. Immunol.* 1999, 29, 3945–3950.

9. Yu, C.L.; Meyer, D.J.; Campbell, G.S.; Larner, A.C.; Carter-Su, C.; Schwartz, J.; Jove, R. Enhanced DNA-binding activity of a STAT3-related protein in cells transformed by the Src oncoprotein. *Science* 1995, 269, 81–83.

10. Wen, Z.; Darnell, J.E., Jr. Mapping of STAT3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of stat1 and stat3. *Nucleic Acids Res.* 1997, 25, 2062–2067.

11. Qin, H.R.; Kim, H.J.; Kim, J.Y.; Hurt, E.M.; Klarmann, G.J.; Kawasaki, B.T.; Serrat, M.A.D.; Farrar, W.L. Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation. *Cancer Res.* 2008, 68, 7736–7741.
12. Bousquet, C.; Susini, C.; Melmed, S. Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. *J. Clin. Investig.* 1999, 104, 1277–1285.

13. Chung, C.D.; Liao, J.; Liu, B.; Rao, X.; Jay, P.; Berta, P.; Shuai, K. Specific inhibition of STAT3 signal transduction by PIAS3. *Science* 1997, 278, 1803–1805.

14. Starr, R.; Willson, T.A.; Viney, E.M.; Murray, L.J.; Rayner, J.R.; Jenkins, B.J.; Gonda, T.J.; Alexander, W.S.; Metcalf, D.; Nicola, N.A.; *et al.* A family of cytokine-inducible inhibitors of signalling. *Nature* 1997, 387, 917–921.

15. Abou-Ghazal, M.; Yang, D.S.; Qiao, W.; Reina-Ortiz, C.; Wei, J.; Kong, L.Y.; Fuller, G.N.; Hiraoka, N.; Pribe, W.; Sawaya, R.; *et al.* The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. *Clin. Cancer Res.* 2008, 14, 8228–8235.

16. Alvarez, J.V.; Mukherjee, N.; Chakravarti, A.; Robe, P.; Zhai, G.; Chakladar, A.; Loeffler, J.; Black, P.; Frank, D.A. A STAT3 gene expression signature in gliomas is associated with a poor prognosis. *Transl. Oncogenomics* 2007, 2, 99–105.

17. Lo, H.W.; Cao, X.; Zhu, H.; Ali-Osman, F. Constitutively activated Stat3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to iressa and alkylators. *Clin. Cancer Res.* 2008, 14, 6042–6054.

18. Lo, H.W.; Hsu, S.C.; Ali-Seyed, M.; Gunduz, M.; Xia, W.; Wei, Y.; Bartholomeusz, G.; Shih, J.Y.; Hung, M.C. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. *Cancer Cell* 2005, 7, 575–589.

19. Lo, H.W.; Hsu, S.C.; Xia, W.; Cao, X.; Shih, J.Y.; Wei, Y.; Abbruzzese, J.L.; Hortobagyi, G.N.; Hung, M.C. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of twist gene expression. *Cancer Res.* 2007, 67, 9066–9076.

20. Ecker, A.; Simma, O.; Hoelbl, A.; Kenner, L.; Beug, H.; Moriggl, R.; Sexl, V. The dark and the bright side of STAT3: Proto-oncogene and tumor-suppressor. *Front. Biosci.* 2009, 14, 2944–2958.

21. Cleveenger, C.V. Roles and regulation of stat family transcription factors in human breast cancer. *Am. J. Pathol.* 2004, 165, 1449–1460.

22. Ling, X.; Arlinghaus, R.B. Knockdown of STAT3 expression by rna interference inhibits the induction of breast tumors in immunocompetent mice. *Cancer Res.* 2005, 65, 2532–2536.

23. Chan, K.S.; Sano, S.; Kiguchi, K.; Anders, J.; Komazawa, N.; Takeda, J.; DiGiovanni, J. Disruption of STAT3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. *J. Clin. Investig.* 2004, 114, 720–728.

24. Pedrazzini, L.; Leitch, A.; Bromberg, J. STAT3 is required for the development of skin cancer. *J. Clin. Investig.* 2004, 114, 619–622.

25. De la Iglesia, N.; Konopka, G.; Puram, S.V.; Chan, J.A.; Bachoo, R.M.; You, M.J.; Levy, D.E.; Depinho, R.A.; Bonni, A. Identification of a pten-regulated STAT3 brain tumor suppressor pathway. *Genes Dev.* 2008, 22, 449–462.

26. Seidel, H.M.; Milocco, L.H.; Lamb, P.; Darnell, J.E., Jr.; Stein, R.B.; Rosen, J. Spacing of palindromic half sites as a determinant of selective stat (signal transducers and activators of
transcription) DNA binding and transcriptional activity. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 3041–3045.

27. Yang, E.; Lerner, L.; Besser, D.; Darnell, J.E. Independent and cooperative activation of chromosomal c-fos promoter by STAT3. *J. Biol. Chem.* **2003**, *278*, 15794–15799.

28. Niu, G.; Briggs, J.; Deng, J.; Ma, Y.; Lee, H.; Kortylewski, M.; Kujawski, M.; Kay, H.; Cress, W.D.; Jove, R.; *et al.* Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. *Mol. Cancer Res.* **2008**, *6*, 1099–1105.

29. Kiuchi, N.; Nakajima, K.; Ichiba, M.; Fukada, T.; Narimatsu, M.; Mizuno, K.; Hibi, M.; Hirano, T. STAT3 is required for the gp130-mediated full activation of the c-myc gene. *J. Exp. Med.* **1999**, *189*, 63–73.

30. Foshay, K.M.; Gallicano, G.I. Regulation of Sox2 by STAT3 initiates commitment to the neural precursor cell fate. *Stem Cells Dev.* **2008**, *17*, 269–278.

31. Okumura, F.; Okumura, A.J.; Matsumoto, M.; Nakayama, K.I.; Hatakeyama, S. TRIM8 regulates nanog via Hsp90beta-mediated nuclear translocation of STAT3 in embryonic stem cells. *Biochim. Biophys. Acta* **2011**, *1813*, 1784–1792.

32. Xiong, H.; Hong, J.; Du, W.; Lin, Y.W.; Ren, L.L.; Wang, Y.C.; Su, W.Y.; Wang, J.L.; Cui, Y.; Wang, Z.H.; *et al.* Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. *J. Biol. Chem.* **2012**, *287*, 5819–5832.

33. Niu, G.; Wright, K.L.; Ma, Y.; Wright, G.M.; Huang, M.; Irby, R.; Briggs, J.; Karras, J.; Cress, W.D.; Pardoll, D.; *et al.* Role of STAT3 in regulating p53 expression and function. *Mol. Cell. Biol.* **2005**, *25*, 7432–7440.

34. Wang, Z.; Zhu, S.; Shen, M.; Liu, J.; Wang, M.; Li, C.; Wang, Y.; Deng, A.; Mei, Q. STAT3 is involved in esophageal carcinogenesis through regulation of Oct-1. *Carcinogenesis* **2013**, *34*, 678–688.

35. Choi, H.J.; Han, J.S. Overexpression of phospholipase D enhances Bcl-2 expression by activating STAT3 through independent activation of ERK and p38MAPK in HeLa cells. *Biochim. Biophys. Acta* **2012**, *1823*, 1082–1091.

36. Becker, T.M.; Boyd, S.C.; Mijatov, B.; Gowrishankar, K.; Snoyman, S.; Pupo, G.M.; Scolyer, R.A.; Mann, G.J.; Kefford, R.F.; Zhang, X.D.; *et al.* Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. *Oncogene* **2013**, *33*, 1158–1166.

37. Epling-Burnette, P.K.; Liu, J.H.; Catlett-Falcone, R.; Turkson, J.; Oshiro, M.; Kothapalli, R.; Li, Y.; Wang, J.M.; Yang-Yen, H.F.; Karras, J.; *et al.* Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. *J. Clin. Investig.* **2001**, *107*, 351–362.

38. Catlett-Falcone, R.; Landowski, T.H.; Oshiro, M.M.; Turkson, J.; Levitzki, A.; Savino, R.; Ciliberto, G.; Moscinski, L.; Fernandez-Luna, J.L.; Nunez, G.; *et al.* Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. *Immunity* **1999**, *10*, 105–115.

39. Gritsko, T.; Williams, A.; Turkson, J.; Kaneko, S.; Bowman, T.; Huang, M.; Nam, S.; Eweis, I.; Diaz, N.; Sullivan, D.; *et al.* Persistent activation of STAT3 signaling induces survivin gene
expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 2006, 12, 11–19.

40. Ivanov, V.N.; Bhoumik, A.; Krasilnikov, M.; Raz, R.; Owen-Schaub, L.B.; Levy, D.; Horvath, C.M.; Ronai, Z. Cooperation between STAT3 and c-Jun suppresses fas transcription. Mol. Cell 2001, 7, 517–528.

41. Madamanchi, N.R.; Li, S.; Patterson, C.; Runge, M.S. Thrombin regulates vascular smooth muscle cell growth and heat shock proteins via the JAK-STAT pathway. J. Biol. Chem. 2001, 276, 18915–18924.

42. Chen, X.S.; Zhang, Y.; Wang, J.S.; Li, X.Y.; Cheng, X.K.; Zhang, Y.; Wu, N.H.; Shen, Y.F. Diverse effects of STAT1 on the regulation of Hsp90alpha gene under heat shock. J. Cell. Biochem. 2007, 102, 1059–1066.

43. Bromberg, J.F.; Wrzeszczynska, M.H.; Devgan, G.; Zhao, Y.; Pestell, R.G.; Albanese, C.; Darnell, J.E., Jr. STAT3 as an oncogene. Cell 1999, 98, 295–303.

44. Leslie, K.; Lang, C.; Devgan, G.; Azare, J.; Berishaj, M.; Gerald, W.; Kim, Y.B.; Paz, K.; Darnell, J.E.; Albanese, C.; et al. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res. 2006, 66, 2544–2552.

45. Sinibaldi, D.; Wharton, W.; Turkson, J.; Bowman, T.; Pledger, W.J.; Jove, R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: Role of activated STAT3 signaling. Oncogene 2000, 19, 5419–5427.

46. Schaefer, A.; Unterberger, C.; Frankenberger, M.; Lohrum, M.; Staples, K.J.; Werner, T.; Stunnenberg, H.; Ziegler-Heitbrock, L. Mechanism of interferon-gamma mediated down-regulation of interleukin-10 gene expression. Mol. Immunol. 2009, 46, 1351–1359.

47. Kortylewski, M.; Xin, H.; Kujawski, M.; Lee, H.; Liu, Y.; Harris, T.; Drake, C.; Pardoll, D.; Yu, H. Regulation of the IL-23 and IL-12 balance by STAT3 signaling in the tumor microenvironment. Cancer Cell 2009, 15, 114–123.

48. Kinjyo, I.; Inoue, H.; Hamano, S.; Fukuyama, S.; Yoshimura, T.; Koga, K.; Takaki, H.; Himeno, K.; Takaesu, G.; Kobayashi, T.; et al. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J. Exp. Med. 2006, 203, 1021–1031.

49. Lo, H.W.; Cao, X.; Zhu, H.; Ali-Osman, F. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol. Cancer Res. 2010, 8, 232–245.

50. Itoh, M.; Murata, T.; Suzuki, T.; Shindoh, M.; Nakajima, K.; Imai, K.; Yoshida, K. Requirement of STAT3 activation for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 2006, 25, 1195–1204.

51. Xie, T.X.; Wei, D.; Liu, M.; Gao, A.C.; Ali-Osman, F.; Sawaya, R.; Huang, S. STAT3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004, 23, 3550–3560.

52. Liu, M.; Wilson, N.O.; Hibbert, J.M.; Stiles, J.K. Stat3 regulates MMP3 in heme-induced endothelial cell apoptosis. PLoS One 2013, 8, e71366.
53. Song, Y.; Qian, L.; Song, S.; Chen, L.; Zhang, Y.; Yuan, G.; Zhang, H.; Xia, Q.; Hu, M.; Yu, M.; et al. Fra-1 and STAT3 synergistically regulate activation of human MMP-9 gene. *Mol. Immun. 2008*, 45, 137–143.

54. Snyder, M.; Huang, X.Y.; Zhang, J.J. Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration. *J. Biol. Chem. 2011*, 286, 38886–38893.

55. Wu, Y.; Diab, I.; Zhang, X.; Izmailova, E.S.; Zehner, Z.E. STAT3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89. *Oncogene 2004*, 23, 168–178.

56. Schiavone, D.; Dewilde, S.; Vallania, F.; Turkson, J.; di Cunto, F.; Poli, V. The Rhou/Wrchi Rho GTPase gene is a common transcriptional target of both the gp130/STAT3 and Wnt-1 pathways. *Biochem. J. 2009*, 421, 283–292.

57. Schuringa, J.J.; Timmer, H.; Luttickhuizen, D.; Vellenga, E.; Kruijer, W. c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 response element (IRE). *Cytokine 2001*, 14, 78–87.

58. Jung, M.; Weigert, A.; Tausendschon, M.; Mora, J.; Oren, B.; Sola, A.; Hotter, G.; Muta, T.; Brune, B. Interleukin-10-induced neutrophil gelatinase-associated lipocalin production in macrophages with consequences for tumor growth. *Mol. Cell. Biol. 2012*, 32, 3938–3948.

59. Bousquet, C.; Zatelli, M.C.; Melmed, S. Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. *J. Clin. Investig. 2000*, 106, 1417–1425.

60. Hagihara, K.; Nishikawa, T.; Sugamata, Y.; Song, J.; Isobe, T.; Taga, T.; Yoshizaki, K. Essential role of STAT3 in cytokine-driven NF-κb-mediated serum amyloid a gene expression. *Genes Cells: Devoted Mol. Cell. Mech. 2005*, 10, 1051–1063.

61. Niu, G.; Wright, K.L.; Huang, M.; Song, L.; Haura, E.; Turkson, J.; Zhang, S.; Wang, T.; Sinibaldi, D.; Coppola, D.; et al. Constitutive STAT3 activity up-regulates vegf expression and tumor angiogenesis. *Oncogene 2002*, 21, 2000–2008.

62. Huang, Y.H.; Wu, M.P.; Pan, S.C.; Su, W.C.; Chen, Y.W.; Wu, L.W. STAT1 activation by venous malformations mutant Tie2-R849W antagonizes VEGF-A-mediated angiogenic response partly via reduced bFGF production. *Angiogenesis 2013*, 16, 207–222.

63. Hung, W.; Elliott, B. Co-operative effect of c-Src tyrosine kinase and STAT3 in activation of hepatocyte growth factor expression in mammary carcinoma cells. *J. Biol. Chem. 2001*, 276, 12395–12403.

64. Nakagawa, K.; Takasawa, S.; Nata, K.; Yamauchi, A.; Itaya-Hironaka, A.; Ota, H.; Yoshimoto, K.; Sakuramoto-Tsuchida, S.; Miyaoka, T.; Takeda, M.; et al. Prevention of Reg I-induced beta-cell apoptosis by IL-6/dexamethasone through activation of HGF gene regulation. *Biochim. Biophys. Acta 2013*, 1833, 2988–2995.

65. Xu, Q.; Briggs, J.; Park, S.; Niu, G.; Kortylewski, M.; Zhang, S.; Gritsko, T.; Turkson, J.; Kay, H.; Semenza, G.L.; et al. Targeting STAT3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. *Oncogene 2005*, 24, 5552–5560.

66. Przanowski, P.; Dabrowski, M.; Ellert-Miklaszewska, A.; Kloss, M.; Mieczkowski, J.; Kaza, B.; Ronowicz, A.; Hu, F.; Piotrowski, A.; Kettenmann, H.; et al. The signal transducers STAT1 and
STAT3 and their novel target JMJD3 drive the expression of inflammatory genes in microglia. 

*J. Mol. Med.** 2013, 92, 239–254.

67. Hamilton, K.E.; Simmons, J.G.; Ding, S.; van Landeghem, L.; Lund, P.K. Cytokine induction of tumor necrosis factor receptor 2 is mediated by STAT3 in colon cancer cells. *Mol. Cancer Res.** 2011, 9, 1718–1731.

68. Lee, H.; Deng, J.; Kujawski, M.; Yang, C.; Liu, Y.; Herrmann, A.; Kortylewski, M.; Horne, D.; Somlo, G.; Forman, S.; et al. STAT3-induced s1pr1 expression is crucial for persistent STAT3 activation in tumors. *Nat. Med.** 2010, 16, 1421–1428.

69. Ahmad, R.; Rajabi, H.; Kosugi, M.; Joshi, M.D.; Alam, M.; Vasir, B.; Kawano, T.; Kharbanda, S.; Kufe, D. MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. *Sci. Signal.** 2011, 4, doi:10.1126/scisignal.2001426.

70. Gaemers, I.C.; Vos, H.L.; Volders, H.H.; van der Valk, S.W.; Hilkens, J. A STAT-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells. *J. Biol. Chem.** 2001, 276, 6191–6199.

71. Oh, H.M.; Yu, C.R.; Golestaneh, N.; Amadi-Obi, A.; Lee, Y.S.; Eseonu, A.; Mahdi, R.M.; Egwuagu, C.E. STAT3 protein promotes T-cell survival and inhibits interleukin-2 production through up-regulation of class o forkhead transcription factors. *J. Biol. Chem.** 2011, 286, 30888–30897.

72. Zorn, E.; Nelson, E.A.; Mohseni, M.; Porcheray, F.; Kim, H.; Litsa, D.; Bellucci, R.; Radorschall, E.; Canning, C.; Soffer, R.J.; et al. IL-2 regulates Foxp3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. *Blood** 2006, 108, 1571–1579.

73. Haviland, R.; Eschrich, S.; Bloom, G.; Ma, Y.; Minton, S.; Jove, R.; Cress, W.D. Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer. *PLoS One** 2011, 6, e24923.

74. Bellido, T.; O’Brien, C.A.; Roberson, P.K.; Manolagas, S.C. Transcriptional activation of the p21 WAF1,CIP1,SDI1 gene by interleukin-6 type cytokines: A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. *J. Biol. Chem.** 1998, 273, 21137–21144.

75. Chin, Y.E.; Kitagawa, M.; Su, W.C.; You, Z.H.; Iwamoto, Y.; Fu, X.Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. *Science** 1996, 272, 719–722.

76. Giraud, S.; Bienvenu, F.; Avril, S.; Gascan, H.; Heery, D.M.; Coqueret, O. Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. *J. Biol. Chem.** 2002, 277, 8004–8011.

77. Abell, K.; Bilancio, A.; Clarkson, R.W.; Tiffen, P.G.; Altaparmakov, A.I.; Burdon, T.G.; Asano, T.; Vanhaesebroeck, B.; Watson, C.J. STAT3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. *Nat. Cell Biol.** 2005, 7, 392–398.

78. Cheng, F.; Wang, H.-W.; Cuenca, A.; Huang, M.; Ghansah, T.; Brayer, J.; Kerr, W.G.; Takeda, K.; Akira, S.; Schoenberger, S.P.; et al. A critical role for STAT3 signaling in immune tolerance. *Immunity** 2003, 19, 425–436.

79. Kang, J.W.; Park, Y.S.; Lee, D.H.; Kim, J.H.; Kim, M.S.; Bak, Y.; Hong, J.; Yoon, D.Y. Intracellular interaction of interleukin (IL)-32alpha with protein kinase cepsilon (pkcepsilon) and STAT3 protein augments IL-6 production in THP-1 promonocytic cells. *J. Biol. Chem.** 2012, 287, 35556–35564.
80. Wang, T.; Niu, G.; Kortylewski, M.; Burdelya, L.; Shain, K.; Zhang, S.; Bhattacharya, R.; Gabrilovich, D.; Heller, R.; Coppola, D.; et al. Regulation of the innate and adaptive immune responses by STAT-3 signaling in tumor cells. *Nat. Med.* **2004**, *10*, 48–54.

81. Chappell, V.L.; Le, L.X.; LaGrone, L.; Mileski, W.J. STAT proteins play a role in tumor necrosis factor alpha gene expression. *Shock* **2000**, *14*, 400–402.

82. Kusaba, H.; Ghosh, P.; Derin, R.; Buchholz, M.; Sasaki, C.; Madara, K.; Longo, D.L. Interleukin-12-induced interferon-gamma production by human peripheral blood T cells is regulated by mammalian target of rapamycin (MTOR). *J. Biol. Chem.* **2005**, *280*, 1037–1043.

83. Yang, J.; Liao, X.; Agarwal, M.K.; Barnes, L.; Auron, P.E.; Stark, G.R. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NF-kb. *Genes Dev.* **2007**, *21*, 1396–1408.

84. Zhang, D.; Sun, M.; Samols, D.; Kushner, I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. *J. Biol. Chem.* **1996**, *271*, 9503–9509.

85. Han, W.; Carpenter, R.L.; Cao, X.; Lo, H.W. STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3. *Mol. Carcinog.* **2013**, *52*, 959–969.

86. Durant, L.; Watford, W.T.; Ramos, H.L.; Laurence, A.; Vahedi, G.; Wei, L.; Takahashi, H.; Sun, H.W.; Kanno, Y.; Powrie, F.; et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. *Immunity* **2010**, *32*, 605–615.

87. Thomas, R.M.; Sai, H.; Wells, A.D. Conserved intergenic elements and DNA methylation cooperate to regulate transcription at the IL17 locus. *J. Biol. Chem.* **2012**, *287*, 25049–25059.

88. Adamson, A.; Ghoreschi, K.; Rittler, M.; Chen, Q.; Sun, H.W.; Vahedi, G.; Kanno, Y.; Stetler-Stevenson, W.G.; O’Shea, J.J.; Laurence, A. Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and Th17 T-helper cell subsets and is a direct stat target gene. *PLoS One* **2013**, *8*, e59367.

89. Bugno, M.; Graeve, L.; Gatsios, P.; Koj, A.; Heinrich, P.C.; Travis, J.; Kordula, T. Identification of the interleukin-6/oncostatin m response element in the rat tissue inhibitor of metalloproteinases-1 (TIMP-1) promoter. *Nucleic Acids Res.* **1995**, *23*, 5041–5047.

90. Coffer, P.; Lutticken, C.; van Puijtenbroek, A.; Klopp-de Jonge, M.; Horn, F.; Kruijer, W. Transcriptional regulation of the junB promoter: Analysis of STAT-mediated signal transduction. *Oncogene* **1995**, *10*, 985–994.

91. Barre, B.; Vigneron, A.; Coqueret, O. The STAT3 transcription factor is a target for the Myc and riboblastoma proteins on the CDC25a promoter. *J. Biol. Chem.* **2005**, *280*, 15673–15681.

92. Shaulian, E. Ap-1—the jun proteins: Oncogenes or tumor suppressors in disguise? *Cell. Signal.* **2010**, *22*, 894–899.

93. Weidemann, A.; Johnson, R.S. Biology of HIF-1α. *Cell Death Differ.* **2008**, *15*, 621–627.

94. Jung, J.E.; Lee, H.G.; Cho, I.H.; Chung, D.H.; Yoon, S.H.; Yang, Y.M.; Lee, J.W.; Choi, S.; Park, J.W.; Ye, S.K.; et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. *FASEB J.* **2005**, *19*, 1296–1298.

95. Ji, J.; Wang, X.W. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. *Semin. Oncol.* **2012**, *39*, 461–472.

96. Hindley, C.; Philpott, A. The cell cycle and pluripotency. *Biochem. J.* **2013**, *451*, 135–143.
97. Philip, B.; Ito, K.; Moreno-Sanchez, R.; Ralph, S.J. HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis 2013, 34, 1699–1707.

98. Sanchez-Tillo, E.; Liu, Y.; de Barrios, O.; Siles, L.; Fanlo, L.; Cuatrecasas, M.; Darling, D.S.; Dean, D.C.; Castells, A.; Postigo, A. Emt-activating transcription factors in cancer: Beyond emt and tumor invasiveness. Cell. Mol. Life Sci. 2012, 69, 3429–3456.

99. Kang, J.; Shakya, A.; Tantin, D. Stem cells, stress, metabolism and cancer: A drama in two octs. Trends Biochem. Sci. 2009, 34, 491–499.

100. Obinata, D.; Takayama, K.; Urano, T.; Murata, T.; Kumagai, J.; Fujimura, T.; Ikeda, K.; Horie-Inoue, K.; Homma, Y.; Ouchi, Y.; et al. Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. Int. J. Cancer J. Int. Cancer 2012, 130, 1021–1028.

101. Wang, M.L.; Chiou, S.H.; Wu, C.W. Targeting cancer stem cells: Emerging role of Nanog transcription factor. Onco Targets Ther. 2013, 6, 1207–1220.

102. Levine, A.J.; Oren, M. The first 30 years of p53: Growing ever more complex. Nat. Rev. Cancer 2009, 9, 749–758.

103. Chao, J.-R.; Wang, J.-M.; Lee, S.-F.; Peng, H.-W.; Lin, Y.-H.; Chou, C.-H.; Li, J.-C.; Huang, H.-M.; Chou, C.-K.; Kuo, M.-L.; et al. McI-i is an immediate-early gene activated by the granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response. Mol. Cell. Biol. 1998, 18, 4883–4898.

104. Wang, J.-M.; Chao, J.-R.; Chen, W.; Kuo, M.-L.; Yen, J.J.-Y.; Yang-Yen, H.-F. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/AKT signaling pathway through a transcription factor complex containing creb. Mol. Cell. Biol. 1999, 19, 6195–6206.

105. Oskay Halacli, S.; Halacli, B.; Altundag, K. The significance of heat shock proteins in breast cancer therapy. Med. Oncol. 2013, 30, doi:10.1007/s12032-013-0575-y.

106. Bertoli, C.; Skotheim, J.M.; de Bruin, R.A. Control of cell cycle transcription during G1 and S phases. Nat. Rev. Mol. Cell Biol. 2013, 14, 518–528.

107. Kortylewski, M.; Kujawski, M.; Wang, T.; Wei, S.; Zhang, S.; Pilon-Thomas, S.; Niu, G.; Kay, H.; Mule, J.; Kerr, W.G.; et al. Inhibiting STAT3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11, 1314–1321.

108. Kitamura, H.; Kamon, H.; Sawa, S.; Park, S.J.; Katunuma, N.; Ishihara, K.; Murakami, M.; Hirano, T. IL-6-STAT3 controls intracellular MHC class II αβ dimer level through cathepsin s activity in dendritic cells. Immunity 2005, 23, 491–502.

109. Benkhart, E.M.; Siedlar, M.; Wedel, A.; Werner, T.; Ziegler-Heitbrock, H.W. Role of STAT3 in lipopolysaccharide-induced IL-10 gene expression. J. Immunol. 2000, 165, 1612–1617.

110. Ziegler-Heitbrock, L.; Lotzerich, M.; Schaefer, A.; Werner, T.; Frankenberger, M.; Benkhart, E. IFN-α induces the human IL-10 gene by recruiting both ifn regulatory factor 1 and STAT3. J. Immunol. 2003, 171, 285–290.

111. Langowski, J.L.; Zhang, X.; Wu, L.; Mattson, J.D.; Chen, T.; Smith, K.; Basham, B.; McClanahan, T.; Kastelein, R.A.; Oft, M. IL-23 promotes tumour incidence and growth. Nature 2006, 442, 461–465.

112. Cheng, J.; Fan, X.M. Role of cyclooxygenase-2 in gastric cancer development and progression. World J. Gastroenterol. 2013, 19, 7361–7368.
113. Zugowski, C.; Lieder, F.; Muller, A.; Gasch, J.; Corvinus, F.M.; Moriggl, R.; Friedrich, K. STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biol. Chem. 2011, 392, 449–459.

114. Dechow, T.N.; Pedrazzini, L.; Leitch, A.; Leslie, K.; Gerald, W.L.; Linkov, I.; Bromberg, J.F. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by STAT3-c. Proc. Natl. Acad. Sci. USA 2004, 101, 10602–10607.

115. Chen, L.; Yang, S.; Jakoniec, J.; Zhang, J.J.; Huang, X.Y. Migrastatin analogues target fascin to block tumour metastasis. Nature 2010, 464, 1062–1066.

116. Chuang, Y.Y.; Valster, A.; Coniglio, S.J.; Backer, J.M.; Symons, M. The atypical Rho family GTPase Wrch-1 regulates focal adhesion formation and cell migration. J. Cell Sci. 2007, 120, 1927–1934.

117. Ory, S.; Brazier, H.; Blangy, A. Identification of a bipartite focal adhesion localization signal in Rhou/Wrch-1, a Rho family GTPase that regulates cell adhesion and migration. Biol. Cell 2007, 99, 701–716.

118. Kobayashi, H.; Boelte, K.C.; Lin, P.C. Endothelial cell adhesion molecules and cancer progression. Curr. Med. Chem. 2007, 14, 377–386.

119. Veitonmaki, N.; Hansson, M.; Zhan, F.; Sundberg, A.; Lofstedt, T.; Ljungars, A.; Li, Z.C.; Martinsson-Niskanen, T.; Zeng, M.; Yang, Y.; et al. A human icam-1 antibody isolated by a function-first approach has potent macrophage-dependent antitymoma activity in vivo. Cancer Cell 2013, 23, 502–515.

120. Zhu, X.W.; Gong, J.P. Expression and role of icam-1 in the occurrence and development of hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 2013, 14, 1579–1583.

121. Chakraborty, S.; Kaur, S.; Guha, S.; Batra, S.K. The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys. Acta 2012, 1826, 129–169.

122. Sherbet, G.V. Hormonal influences on cancer progression and prognosis. Vitam. Horm. 2005, 71, 147–200.

123. Malle, E.; Sodin-Semrl, S.; Kovacevic, A. Serum amyloid A: An acute-phase protein involved in tumour pathogenesis. Cell. Mol. Life Sci. 2009, 66, 9–26.

124. Deng, J.; Liang, H.; Zhang, R.; Sun, D.; Pan, Y.; Liu, Y.; Zhang, L.; Hao, X. STAT3 is associated with lymph node metastasis in gastric cancer. Tumour Biol. 2013, 34, 2791–2800.

125. Huang, X.; Meng, B.; Iqbal, J.; Ding, B.B.; Perry, A.M.; Cao, W.; Smith, L.M.; Bi, C.; Jiang, C.; Greiner, T.C.; et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-chop. J. Clin. Oncol. 2013, 31, 4520–4528.

126. Xu, Y.H.; Lu, S. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer. Eur. J. Surg. Oncol. 2014, 40, 311–317.

127. Zetter, B.R. The scientific contributions of M. Judah Folkman to cancer research. Nat. Rev. Cancer 2008, 8, 647–654.

128. Megeney, L.A.; Perry, R.L.; LeCouter, J.E.; Rudnicki, M.A. bFGF and LIF signaling activates STAT3 in proliferating myoblasts. Dev. Genet. 1996, 19, 139–145.

129. Cheung, M.; Testa, J.R. Diverse mechanisms of AKT pathway activation in human malignancy. Curr. Cancer Drug Targets 2013, 13, 234–244.
130. Blanco-Aparicio, C.; Carnero, A. Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities. Biochem. Pharmacol. 2013, 85, 629–643.

131. Shirogane, T.; Fukada, T.; Muller, J.M.; Shima, D.T.; Hibi, M.; Hirano, T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999, 11, 709–719.

132. Mizoguchi, E.; Mizoguchi, A.; Takedatsu, H.; Cario, E.; de Jong, Y.P.; Ooi, C.J.; Xavier, R.J.; Terhorst, C.; Podolsky, D.K.; Bhan, A.K. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology 2002, 122, 134–144.

133. Kunkel, G.T.; Maceyka, M.; Milstien, S.; Spiegel, S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat. Rev. Drug Discov. 2013, 12, 688–702.

134. Kufe, D.W. MUC1-C oncoprotein as a target in breast cancer: Activation of signaling pathways and therapeutic approaches. Oncogene 2013, 32, 1073–1081.

135. Zhang, Y.; Gan, B.; Liu, D.; Paik, J.H. Foxo family members in cancer. Cancer Biol. Ther. 2011, 12, 253–259.

136. Douglass, S.; Ali, S.; Meeson, A.P.; Browell, D.; Kirby, J.A. The role of FOXP3 in the development and metastatic spread of breast cancer. Cancer Metastasis Rev. 2012, 31, 843–854.

137. Asai, T.; Liu, Y.; Nimer, S.D. Necdin, a p53 target gene, in stem cells. Oncotarget 2013, 4, 806–807.

138. Hasegawa, K.; Yoshikawa, K. Necdin regulates p53 acetylation via sirtuin1 to modulate DNA damage response in cortical neurons. J. Neurosci. 2008, 28, 8772–8784.

139. Chapman, R.S.; Lourenco, P.C.; Tonner, E.; Flint, D.J.; Selbert, S.; Takeda, K.; Akira, S.; Clarke, A.R.; Watson, C.J. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of STAT3. Genes Dev. 1999, 13, 2604–2616.

140. Allin, K.H.; Nordestgaard, B.G. Elevated c-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit. Rev. Clin. Lab. Sci. 2011, 48, 155–170.

141. Kolev, M.; Towner, L.; Donev, R. Complement in cancer and cancer immunotherapy. Arch. Immunol. Ther. Exp. 2011, 59, 407–419.

142. Koromilas, A.E.; Sexl, V. The tumor suppressor function of STAT1 in breast cancer. JAK-STAT 2013, 2, e23353.

143. Ernst, M.; Najdovska, M.; Grail, D.; Lundgren-May, T.; Buchert, M.; Tye, H.; Matthews, V.B.; Armes, J.; Bhathal, P.S.; Hughes, N.R.; et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Investig. 2008, 118, 1727–1738.

144. Harrington, L.E.; Hatton, R.D.; Mangan, P.R.; Turner, H.; Murphy, T.L.; Murphy, K.M.; Weaver, C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6, 1123–1132.

145. Park, H.; Li, Z.; Yang, X.O.; Chang, S.H.; Nurieva, R.; Wang, Y.H.; Wang, Y.; Hood, L.; Zhu, Z.; Tian, Q.; et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 2005, 6, 1133–1141.

146. Qi, W.; Huang, X.; Wang, J. Correlation between Th17 cells and tumor microenvironment. Cell. Immunol. 2013, 285, 18–22.
147. Ye, J.; Livergood, R.S.; Peng, G. The role and regulation of human Th17 cells in tumor immunity. *Am. J. Pathol.* **2013**, *182*, 10–20.

148. Wurtz, S.O.; Schrohl, A.S.; Sorensen, N.M.; Lademann, U.; Christensen, I.J.; Mouridsen, H.; Brunner, N. Tissue inhibitor of metalloproteinases-1 in breast cancer. *Endocr.-Relat. Cancer* **2005**, *12*, 215–227.

149. Janakiram, N.B.; Rao, C.V. Inos-selective inhibitors for cancer prevention: Promise and progress. *Future Med. Chem.* **2012**, *4*, 2193–2204.

150. Johnson, E.S.; Kornbluth, S. Phosphatases driving mitosis: Pushing the gas and lifting the brakes. *Prog. Mol. Biol. Transl. Sci.* **2012**, *106*, 327–341.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).